Abstract
(Anesthesiology 2016;124:378–386) Oxytocin remains the first-line uterotonic agent for the prevention and treatment of postpartum hemorrhage (PPH) secondary to uterine atony, but its routine use has limitations that include many side effects. Hence there is a search for newer agents for the prevention of PPH with greater efficacy and fewer side effects. The objective of this study was to compare the effects of oxytocin and carbetocin in human term pregnant myometrium in vitro, with and without oxytocin pretreatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
